Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer
- PMID: 26829230
- DOI: 10.2217/fon.15.356
Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer
Abstract
Nonadvanced non-small-cell lung cancer (NSCLC) has a poor long-term survival from surgery or definitive radiation that is minimally improved with induction/adjuvant conventional chemotherapy. EGFR-tyrosine kinase inhibitors (TKIs), which provide a significant benefit for molecularly selected EGFR-mutant patients with advanced NSCLC, have been infrequently explored in nonadvanced NSCLC to date. Current published studies reported no significant benefit from adding EGFR-TKI to the induction/adjuvant setting. However, many of them present eventual biases such as unpowered statistics, lack of molecular selection, recruitment of low-risk NSCLC, low sample size or unsuitable control arms. Results, strengths and deficiencies of completed and ongoing trials were fully discussed. Similarly, the selection of patients and control arms, the duration and risks of EGFR-TKI therapies in early-stage NSCLC, the evaluation of response and the diagnosis of EGFR status were considered and analyzed.
Keywords: EGFR-tyrosine kinase inhibitor; adjuvant treatment; early stage; induction treatment; locally advanced stage; non-small-cell lung cancer.
Similar articles
-
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8. Lung Cancer. 2016. PMID: 26898616 Review.
-
Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.Curr Opin Oncol. 2015 Mar;27(2):102-7. doi: 10.1097/CCO.0000000000000163. Curr Opin Oncol. 2015. PMID: 25611026 Review.
-
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.Future Oncol. 2015 Sep;11(18):2525-40. doi: 10.2217/fon.15.183. Epub 2015 Aug 28. Future Oncol. 2015. PMID: 26314834 Review.
-
Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients.Clin Adv Hematol Oncol. 2016 Jan;14(1):41-3. Clin Adv Hematol Oncol. 2016. PMID: 27057666 Review.
-
Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?Drug Des Devel Ther. 2015 Oct 15;9:5641-53. doi: 10.2147/DDDT.S52787. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26508839 Free PMC article. Review.
Cited by
-
EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?Cells. 2021 Aug 21;10(8):2157. doi: 10.3390/cells10082157. Cells. 2021. PMID: 34440926 Free PMC article. Review.
-
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21. Toxicol Appl Pharmacol. 2017. PMID: 28942004 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
